Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 199,093 |
|
|||||
| News | - | ||||||
| Day High | 16.28 | Low High |
|||||
| Day Low | 15.52 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| REGENXBIO Inc | RGNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.26 | 1.66% | 15.90 | 15:41:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.67 | 15.52 | 16.28 | 15.64 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,288 | 199,093 | $ 16.00 | $ 3,185,156 | - | 11.83 - 28.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:41:54 | 100 | $ 15.90 | USD |
REGENXBIO Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 708.18M | 44.43M | - | 90.24M | -263.49M | -5.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
REGENXBIO News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 17.83 | 18.24 | 15.18 | 16.26 | 456,450 | -1.93 | -10.82% |
| 1 Month | 21.88 | 22.42 | 15.18 | 18.95 | 465,855 | -5.98 | -27.33% |
| 3 Months | 12.85 | 28.80 | 11.83 | 19.44 | 773,246 | 3.05 | 23.74% |
| 6 Months | 15.99 | 28.80 | 11.83 | 18.36 | 649,669 | -0.09 | -0.56% |
| 1 Year | 19.12 | 28.80 | 11.83 | 18.38 | 514,110 | -3.22 | -16.84% |
| 3 Years | 34.70 | 46.46 | 11.83 | 24.63 | 434,891 | -18.80 | -54.18% |
| 5 Years | 50.06 | 55.23 | 11.83 | 30.84 | 443,248 | -34.16 | -68.24% |
REGENXBIO Description
| Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). |
